Daniel L. Clarke‐Pearson

Author

Also Known As

Barber, Emma L., Chalas, Eva, Clarke-Pearson, Daniel L, D CLARKEPEARSON, D Clarke-Pearson, D L Clarke-Pearson, D. CLARKE-PEARSON, D. Clarke-Pearson, D. L. CLARKE-PEARSON, D. L. Clarke-Pearson

285

Publications

46.6K

Citations

H-Index

129

Concepts

All Affiliations

Duke Medical Center Duke University Duke University Hospital University of North Carolina at Chapel Hill Gynecologic Oncology Group

About

Daniel L. Clarke‐Pearson is an author at Duke Medical Center specializing in medicine, obstetrics, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	51	105	7.9K
2	Public Health	15	16	22.5K
3	Health Sciences	7	7	314
4	Arts	1	1	48
5	Engineering	1	1	21.5K

Daniel L. Clarke‐Pearson

153

Publications

44.2K

Citations

H-Index

Page 1

	Year	Citations
Comparing the Areas under Two or More Correlated Receiver Operating Characteristic Curves: A Nonparametric Approach Elizabeth R. DeLong, David M. DeLong, Daniel L. Clarke‐Pearson Biometrics EngineeringNew TestsGeneralizability TheoryStatistical FoundationDiagnosis	1988	21.5K
Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer William P. McGuire, William J. Hoskins, Mark F. Brady, New England Journal of Medicine	1996	2.9K
Concurrent Cisplatin-Based Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer Peter G. Rose, Brian N. Bundy, E. Blake Watkins, New England Journal of Medicine	1999	2.6K
Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study Robert F. Ozols, Brian N. Bundy, Benjamin E. Greer, Journal of Clinical Oncology	2003	2K
Randomized Comparison of Fluorouracil Plus Cisplatin Versus Hydroxyurea as an Adjunct to Radiation Therapy in Stage IIB-IVA Carcinoma of the Cervix With Negative Para-Aortic Lymph Nodes: A Gynecologic Oncology Group and Southwest Oncology Group Study Charles W. Whitney, William T. Sause, Brian N. Bundy, Journal of Clinical Oncology	1999	1.5K
Intraperitoneal Cisplatin plus Intravenous Cyclophosphamide versus Intravenous Cisplatin plus Intravenous Cyclophosphamide for Stage III Ovarian Cancer David S. Alberts, P. Y. Liu, Edward V. Hannigan, New England Journal of Medicine	1996	1.2K
Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Andrew Berchuck, Ayman H. Kamel, Regina S. Whitaker, PubMed Breast OncologyOncologyMedicineExternal DomainGynecology	1990	765
Evaluation of Monoclonal Humanized Anti-HER2 Antibody, Trastuzumab, in Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Carcinoma With Overexpression of HER2: A Phase II Trial of the Gynecologic Oncology Group Michael A. Bookman, Kathleen M. Darcy, Daniel L. Clarke‐Pearson, Journal of Clinical Oncology	2003	610
Overexpression and mutation of p53 in epithelial ovarian cancer. Jeffrey R. Marks, A M Davidoff, B. J. Kerns, PubMed Tumoral PathologyCancer PathologyEpithelial Ovarian CancerMedicineP53 Expression	1991	471
Retrospective Analysis of Selective Lymphadenectomy in Apparent Early-Stage Endometrial Cancer Janiel M. Cragun, Laura J. Havrilesky, Brian Calingaert, Journal of Clinical Oncology	2005	444

Page 1